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Abstract
CHARGE syndrome is characterized by a pattern of congenital anomalies (Coloboma
of the eye, Heart defects, Atresia of the choanae, Retardation of growth, Genital
abnormalities, and Ear abnormalities). De novo mutations of chromodomain helicase
DNA binding protein 7 (CHD7) are the primary cause of CHARGE syndrome. The
clinical phenotype is highly variable including a wide spectrum of congenital heart
defects. Here, we review the range of congenital heart defects and the molecular
effects of CHD7 on cardiovascular development that lead to an over-representation
of atrioventricular septal, conotruncal, and aortic arch defects in CHARGE syndrome.
Further, we review the overlap of cardiovascular and noncardiovascular com-
orbidities present in CHARGE and their impact on the peri-operative morbidity and
mortality in individuals with CHARGE syndrome.
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1 | INTRODUCTION
CHARGE syndrome is a rare genetic disorder (OMIM 214800) with an
estimated incidence of approximately 1 in 10,000 (Issekutz, Graham,
Prasad, Smith, & Blake, 2005). CHARGE syndrome was initially
described as a pattern of anomalies by Hall (1979) and Hittner, Hirsch,
Kreh, and Rudolph (1979) that was formally defined as an association
by (Pagon, Graham, Zonana, & Yong, 1981). The primary features of
CHARGE—ocular coloboma (C), heart malformations (H), atresia of the
choanae (A), retardation of growth (R), genital hypoplasia (G), and ear
abnormalities (E)—form an acronym that serves as the name of the
condition. CHARGE was subsequently defined as a syndrome with
the identification of autosomal dominant pathogenic variants in the
CHD7 gene in 2004 (Vissers et al., 2004), which occurs in 58–90% of
patients with CHARGE syndrome (Jongmans et al., 2006; Lalani et al.,
2006; Legendre et al., 2017; Zentner, Layman, Martin, & Scacheri,
2010). An additional spectrum of single gene pathogenic variants have
been identified in individuals with the clinical features of CHARGE
(Moccia et al., 2018).
Since the identification of CHD7 and further refinement of spe-
cific features of inner ear formation, diagnostic criteria for the
syndrome have undergone multiple revisions (Blake et al., 1998; Hale,
Niederriter, Green, & Martin, 2016; Sanlaville & Verloes, 2007;
Verloes, 2005). Heart malformations remain a key criterion for the
definitions of the syndrome. While there is a highly variable cardiac
phenotype, cardiac defects convey significant implications for the clin-
ical course of individuals with CHARGE syndrome. In this review, we
will discuss the spectrum of congenital heart disease in CHARGE syn-
drome, the clinical impact of CHARGE syndrome on outcomes in
congenital heart disease, and our current understanding of the mecha-
nisms of action of CHARGE syndrome in cardiac development.
2 | PATTERNS OF CONGENITAL HEART
DISEASE IN CHARGE
2.1 | Types of congenital heart disease in CHARGE
The spectrum of congenital heart disease is highly variable in
CHARGE syndrome and encompasses mild cardiac malformations
(e.g., patent ductus arteriosus [PDA] and atrial septal defects)
that may not require intervention to more severe malformations
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(e.g., Tetralogy of Fallot) that require cardiothoracic surgery in infancy.
Conotruncal defects (31–42%) and atrioventricular septal defects
(AVSDs; 13–17%) with associated or isolated PDA and aortic arch
abnormalities are seen more frequently in individuals with CHARGE
than the full population of patients with congenital heart disease
(Corsten-Janssen, Kerstjens-Frederikse, et al., 2013; Corsten-Janssen,
Saitta, et al., 2013; Corsten-Janssen, van Ravenswaaij-Arts, & Kapusta,
2016; Lin, Chin, Devine, Park, & Zackai, 1987; Vissers et al., 2004;
Wyse, Al-Mahdawi, Burn, & Blake, 1993).
We characterized this further by compiling all large case series/
cohort studies (>4 patients) with published detail sufficient for classifi-
cation of congenital heart disease types and compared these to the
largest meta-analysis to date of all congenital cardiac defects (Table 1;
Liu, Chen, et al., 2019). The cardiac phenotypes across these studies
were arranged according to the large classifications based off embryo-
logic development using a modified classification system from Botto
et al. (2007). The largest single study of individuals with CHARGE syn-
drome examining the spectrum of congenital heart defects included
299 individuals with CHARGE syndrome (Corsten-Janssen, Kerstjens-
Frederikse, et al., 2013; Corsten-Janssen, Saitta, et al., 2013). This
large study aligns well with the data found in the composite of the
additional studies (Table 1) and demonstrates the over-representation
of conotruncal defects and AVSDs (Figure 1). Often overlapping
within these larger classification categories is a high incidence of
aortic arch abnormalities (e.g., right aortic arch and aberrant right
subclavian arteries) and additional presence of a PDA (Corsten-
Janssen et al., 2016). Despite this bias toward conotruncal and AVSD
defects, the incidence of CHARGE syndrome remains rare enough
that specifically screening for CHARGE in patients with heart defects
plus an additionally involved organ system is not cost-effective
(Corsten-Janssen et al., 2014; Corsten-Janssen & Scambler, 2017).
Given the range of pathogenic variants seen in CHARGE syndrome
(Moccia et al., 2018; Zentner et al., 2010), it is important to understand
the impact of causative CHD7 variants on the CHARGE syndrome
TABLE 1 Spectrum of congenital heart disease in CHARGE syndrome versus all congenital heart disease
CHARGE syndrome All CHD
Primary classification (modified from














Conotruncal 88 54 142 33.6 0.876 10.2
Atrioventricular Septal defect 22 26 48 11.3 0.290 3.4
Right ventricular outflow tract
malformation
19 20 39 9.2 0.805 9.3
Septal defect 55 58 113 26.7 4.512 52.4
Left ventricular outflow tract
malformation
20 23 43 10.2 0.886 10.3
PDA 15 19 34 8.0 1.004 11.7
Complex single ventricle 2 1 3 0.7 0.093 1.1
Abnormal pulmonary venous return 0 1 1 0.2 0.144 1.7
Number with congenital heart disease 221 202 423 100 Adapted from Liu, Chen,
et al. (2019)
Note. All congenital heart disease data adapted from Liu, Chen, et al. (2019) with meta-analysis across nations and time eras, encompassing 130,758,851
births with congenital heart disease from 1970 to 2017. Congenital heart disease from literature review of all studies >4 CHARGE patients with sufficient
congenital heart disease description to enable classification and with comparison of largest single study by Corsten-Janssen, Kerstjens-Frederikse, et al.
(2013) and Corsten-Janssen, Saitta, et al. (2013). (Aramaki et al., 2006; Blake, Russell-Eggitt, Morgan, Ratcliffe, & Wyse, 1990; Busa et al., 2016;
Corsten-Janssen, Kerstjens-Frederikse, et al., 2013; Corsten-Janssen, Saitta, et al., 2013; Cyran, Martinez, Daniels, Dignan, & Kaplan, 1987; Gennery et al.,
2008; Jongmans et al., 2006; Jongmans et al., 2008; Legendre et al., 2012; Lin et al., 1987; Oley, Baraitser, & Grant, 1988; Strömland et al., 2005; Wyse
et al., 1993).
F IGURE 1 Spectrum of congenital heart disease in CHARGE
syndrome compared to all congenital heart disease. Conotruncal
defects and atrioventricular septal defects (AVSDs) are over-
represented in CHARGE compared to all congenital heart disease
from Table 1. There are fewer isolated septal defects, similar degree
right ventricular outflow tract (RVOT), left ventricular outflow tract
(LVOT), isolated patent ductus arteriosus (PDA), complex single
ventricles (SV), and anomalous pulmonary venous return (APVR)
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cardiac phenotype. Within the spectrum of CHD in CHARGE syndrome,
there appears to be no significant difference in presence of CHD in
patients with or without a CHD7 pathogenic variant (Bergman et al.,
2011; Corsten-Janssen, Kerstjens-Frederikse, et al., 2013; Corsten-
Janssen, Saitta, et al., 2013; Hale et al., 2016; Legendre et al., 2017;
Vissers et al., 2004; Zentner et al., 2010). However, some larger series
suggest an increase in congenital heart disease in CHD7-positive
patients (66–92%) compared to 71% of CHD7-negative patients
(Jongmans et al., 2006; Jyonouchi, McDonald-McGinn, Bale, Zackai, &
Sullivan, 2009; Lalani et al., 2006). Lanali et al. also suggests a higher
incidence of AVSD and PDA in isolation or associated with other lesions
in CHARGE patients with CHD7 pathogenic variants.
For individuals with CHD7-related CHARGE syndrome, the type
of variant in CHD7 had a genotype–phenotype relationship with more
severe phenotypes being associated with truncating variants
(Bergman et al., 2011; Legendre et al., 2017). This includes an
increased burden of congenital heart disease in CHARGE syndrome
which occurs in 70–82% of individuals with a truncating CHD7 variant
compared to 22–64% in individuals with nontruncating variants
(Corsten-Janssen, Kerstjens-Frederikse, et al., 2013; Corsten-Janssen,
Saitta, et al., 2013; Legendre et al., 2017). The primary limitation of
these data to detect more detailed genotype–phenotype relationships
is the sample size in individual studies. The growing repository of large
cohort studies that collect the cardiac phenotype and presence of
CHD7 variant or CHD7 variant type (truncating or nontruncating;
Corsten-Janssen, Kerstjens-Frederikse, et al., 2013; Corsten-Janssen,
Saitta, et al., 2013; Jongmans et al., 2006; Lalani et al., 2006; Legendre
et al., 2017; Vissers et al., 2004; Wincent et al., 2008) should allow for
pooling of these large datasets for more detailed meta-analysis. How-
ever, the overlap of pathogenic variant data and congenital heart
defect phenotype is not routinely presented in most studies, which
prevents data aggregation and meta-analysis and argues for publica-
tion of supplemental datasets including this information.
2.2 | Mechanisms of cardiac malformations in
CHARGE syndrome
2.2.1 | Cardiac development
The heart is the first organ to develop during embryogenesis. It pro-
ceeds primarily from the splanchnic mesoderm, though the endoderm
and ectoderm also play important contributions. The mesoderm forms
the first recognizable heart structure, the primitive heart tube, during
gastrulation. The primitive heart tube forms the first and second heart
fields, with the first heart field forming the inlets (atrioventricular val-
ves and atria), left ventricle, and connections to the systemic and pul-
monary venous pathways (Figure 2a). The second heart field forms
the right ventricle and outflow tract which is initially a single vessel
that then septates into the great arteries with formation of the conal
septum (Verzi, McCulley, De Val, Dodou, & Black, 2005). The outflow
(truncus arteriosus) connects to the dorsal aortae through the
F IGURE 2 Stages of cardiac development. (a) Looping of first and second heart fields demonstrating migration of neural crest cells (NCC) to
the conotruncal out flow tract (OFT) and pharyngeal aortic arches (PAA). Incomplete looping in the right ventricle (RV) or septation of the outflow
tracts results in double outlet right ventricle or other conotruncal defects (e.g., Tetralology of Fallot, transposition of the great arteries).
Incomplete left ventricular (LV) looping results in a double inlet left ventricle and is less common in CHARGE. Atrioventricular valve formation
(AVV) begins in the first heart field (FHF) with additional components from the secondary heart field (SHF). (b) Aortic arch development.
Regression in the aortic arches is heavily influenced by NCCs. Abnormal arch regression can lead to aortic arch defects typically seen in CHARGE.
Examples include persistence of the left VI arch (i.e., patent ductus arteriosus (PDA), regression of the left IV arch leading to development of the
right IV arch and a right aortic arch, and regression of the right IV arch leading to an aberrant right subclavian artery (ARSCA)
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pharyngeal arch arteries (Figure 2b). The heart fields rotate and
expand in size to establish heart looping with the second heart field
moving anterior and rightward.
A complex series of events orchestrates the septation of the
looped heart into four chambers with parts of both the first and second
heart field contributing to the intraventricular septum. As the first and
second heart field loop, the atria and ventricles are brought together at
the crux of the heart, where the endocardium undergoes endothelial to
mesenchymal transition, resulting in swelling and formation of the
endocardial cushions. The cushions then remodel to form the atrioven-
tricular valves. Incomplete anterior–posterior cushion union results in
lack of septation of the atrioventricular valves (i.e., AVSD).
A similar process of cushion formation and rotation occurs at the
level of the outlet to form the great arteries and aortic and pulmonary
valves. Outflow tract cushion formation is dependent on migration of
neuroectodermally derived cells called cardiac neural crest cells (see
reviews [Plein, Fantin, & Ruhrberg, 2015; Stoller & Epstein, 2005]).
Alteration of cardiac neural crest cell function can result in abnormal
rotation (i.e., transposition of the great arteries), lack of outflow tract
cushion development (i.e., truncus arteriosus), or abnormal positioning
(e.g., anterior mal-alignment which results in Tetralogy of Fallot) and
lead to specific patterns of congenital heart defects. Neural crest cells
similarly play a critical role in regression and development of the pha-
ryngeal arches and arch arteries (see review [Plein et al., 2015]).
It is useful to consider the spectrum of congenital heart disease
as arising from patterns of altered migration (e.g., malalignment of the
conal septum leading to Tetralogy of Fallot), incomplete growth
(e.g., AVSD, VSD, or ASD), inappropriate regression (e.g., aberrant
subclavian arteries or right aortic arch), or lack of appropriate regres-
sion (e.g., PDA) (Figure 2b). As such, impaired development within the
first and second heart fields leads to the association of right sided
heart lesions with conoventricular (outlets and conal septum) defects
(e.g., Tetralogy of Fallot, truncus arteriosus, double outlet right ventri-
cle) and association of the left ventricle with inlet abnormalities
(e.g., double inlet left ventricle) (Figure 2a).
Given the increased frequency of conoventricular and arch vessel
defects in CHARGE syndrome and the critical role in neural crest cells in
septation of the outflow tract and conal septum and the pharyngeal
arches, there has been long-standing focus of the involvement of neural
crest cells in CHARGE syndrome (Siebert, Graham, & MacDonald, 1985).
However, as demonstrated by the overrepresentation of AVSD in
CHARGE syndrome and nonessential role of neural crest cells in endo-
cardial cushion formation, additional mechanisms are likely involved in
congenital heart defects associated with CHARGE syndrome.
2.2.2 | CHD7 and associated genes in cardiac
development
Chromodomain helicase DNA binding protein 7 (CHD7, OMIM
608892) and downstream genes are the primary causes of CHARGE
syndrome. CHD7 encodes an ATP-dependent chromatin modifier that
associates with all three forms of methylated H3K4 (Schnetz et al.,
2009). As with chromatin modifiers and epigenetic mechanisms of
cardiac development, CHD7 is broadly expressed in tissues, which
helps to explain its pleiotropic effects.
As suggested by the pattern of cardiac defects and embryology,
there are multiple lines of evidence showing that CHD7 plays a critical
role in neural crest cell development and presents a stereotypic exam-
ple of a neurocristopathy (Pauli, Bajpai, & Borchers, 2017). CHD7 is
known to cooperate with PBAF to control formation of neural crest
cells (Bajpai et al., 2010) and partially regulates Sox10 deregulation in
the neural crest cells (Asad et al., 2016) leading to the CHARGE pheno-
type. Downstream Semaphorin and Robo pathways are critical to neu-
ral crest development and migration and may be involved in CHD7-
negative CHARGE syndrome (S R Lalani et al., 2004; Liu, Guo, et al.,
2019; Schulz et al., 2014; Ufartes et al., 2018). Additionally, there is also
evidence that the disruption of Fam172a, which interacts with CHD7
and Argo2, can affect alternative splicing in neural crest cells and lead
to a CHARGE phenotype (Bélanger et al., 2018), with neural crest cells
being particularly sensitive to disruption of splicing machinery (Bérubé-
Simard & Pilon, 2019). However, not all aspects of CHARGE can be
related to the role of CHD7 on neural crest development. CHD7 is addi-
tionally expressed in the mesoderm of the developing heart. Mesoderm
lineage-specific ablation (Mesp1) of CHD7 leads to disruption of endo-
cardial cushion formation, which may explain the overrepresentation of
AVSD defects in CHARGE syndrome (Payne et al., 2015).
It has been long recognized that there is a clinical overlap between
individuals with CHARGE syndrome and DiGeorge Sequence/22q11.2
microdeletion syndrome (22q11.2 DS) (Corsten-Janssen, Kerstjens-
Frederikse, et al., 2013; Corsten-Janssen, Saitta, et al., 2013; Randall
et al., 2009; Sanka, Tangsinmankong, Loscalzo, Sleasman, & Dorsey,
2007). CHD7 and TBX1 (the locus associated with 22q11.2 DS specific
cardiac defects [Lindsay et al., 2001; Merscher et al., 2001]) are syner-
gistic in cardiac phenotypes of CHARGE (Randall et al., 2009) and both
are partially mediated through effects on p53 (Caprio & Baldini, 2014;
Van Nostrand et al., 2014). There is also an overlap of Kabuki syn-
drome, which is caused with pathogenic variations in lysine-specific
chromatin modifiers (KMT2D, OMIM 602113 and KDM6A, OMIM
300128), which operate through the same chromatin remodeling
machinery as CHD7 and can lead to CHD7-negative CHARGE syn-
drome (Butcher et al., 2017; Moccia et al., 2018; Sakata et al., 2017;
Schulz et al., 2014). Chromatin and abnormal methylation patterning
are also implicated in multifactorial causes of conotruncal defects
(Radhakrishna et al., 2018). Together, these data suggest multiple com-
mon pathways in chromatin biology are necessary for neural crest cell
differentiation and migration.
3 | CLINICAL IMPACT OF CHARGE ON
CHD OUTCOME
Advances in congenital cardiac surgery, preoperative evaluation with
catheterization, and advancing imaging have reduced mortality with
surgical repair of congenital heart disease, but there remains signifi-
cant morbidity and mortality associated with congenital heart disease
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(Gilboa, Salemi, Nembhard, Fixler, & Correa, 2010). Multiple preopera-
tive risk factors contribute to postoperative outcomes; prominent
among these risk factors is extra-cardiac organ system involvement
(Landis, Cooper, & Hinton, 2016). Abnormal development of multiple
organ systems is common in many genetic syndromes and associa-
tions, with cardiac development being the most common (Fahed,
Gelb, Seidman, & Seidman, 2013). As such, individuals with genetic
syndromes and associations represent 20–30% of all congenital
heart disease and have a higher incidence of AVSD, conotruncal
defects, and aortic arch abnormalities that require surgical repair
(Patel et al., 2016).
Individuals with congenital heart disease and a genetic syndrome
or association have increased risk of poorer outcomes compared to
nonsyndromic individuals with congenital heart disease (Alsoufi et al.,
2016; Formigari et al., 2009; Landis et al., 2016; Patel et al., 2010).
However, of the limited studies that dissect the effect of specific
genetic syndromes and associations on outcomes after congenital
heart disease repair, there are large variations in associated morbidity
and mortality ranging from markedly increase risk to relative protec-
tion in surgical outcomes depending on the syndrome (Landis et al.,
2016; Michielon et al., 2009). In CHARGE syndrome, the type of con-
genital heart defects are hemodynamically significant enough to
require surgery in 63–79% of individuals with a congenital heart
defect and often required multiple, staged surgical repairs (Corsten-
Janssen, Kerstjens-Frederikse, et al., 2013; Corsten-Janssen, Saitta,
et al., 2013; Husu et al., 2013; Wyse et al., 1993). The high incidence
of surgical repair, high frequency of staged repair, and multiple organ
systems frequently affected in individuals with CHARGE syndrome
belies the importance of understanding surgical outcomes and factors
to account for in the peri-operative management of individuals of
CHARGE syndrome.
The wide spectrum of congenital heart disease in individuals
with CHARGE syndrome and the rarity of the disease has led to lim-
ited data that specifically isolates the impact of CHARGE on postop-
erative outcomes. The limited data that does exist suggests that
postsurgical outcomes in individuals with CHARGE syndrome are
suboptimal (Michielon et al., 2009; Wyse et al., 1993), and the
highest morbidity and mortality occurs within the neonatal period
(<6 months; Blake et al., 1990; Tellier et al., 1998). The few identified
risks factors for increased morbidity and mortality for individuals
with CHARGE are predominantly airway and feeding abnormalities
(Bergman et al., 2010; Blake et al., 1990; Issekutz et al., 2005; Tellier
et al., 1998; Wyse et al., 1993) but there is additional increased risk
of death with congenital heart disease particularly after the neonatal
period (Bergman et al., 2010; Issekutz et al., 2005). The limited out-
comes data in CHARGE, however, may be insufficient to assess the
impact of the other associated organ system abnormalities that
occur in CHARGE syndrome.
It is important to consider the role of immunodeficiency with the
aforementioned airway and gastrointestinal anomalies on postsurgical
outcomes in CHARGE syndrome. With increased prevalence and
available outcomes data for individuals with 22q11.2, assessing the
impact of 22q11.2 DS on peri-operative outcomes can provide some
insight into CHARGE syndrome given the clinical overlap of cardiac
defects (i.e., conotruncal and aortic arch abnormalities), airway anoma-
lies (i.e., cleft lip and palate), and immunodeficiencies between the
two syndromes (Corsten-Janssen, Kerstjens-Frederikse, et al., 2013;
Corsten-Janssen, Saitta, et al., 2013; Hsu et al., 2016; Jyonouchi et al.,
2009; Randall et al., 2009; Sanka et al., 2007). Outcomes data from
22q11.2 DS suggest mildly increased perioperative morbidity and
increased length of stay, but overall similar long-term outcomes com-
pared to nonsyndromic repair of matched congenital heart disease
(Alsoufi et al., 2017; McDonald et al., 2013; Mercer-Rosa, Elci, Pinto,
Tanel, & Goldmuntz, 2018; Michielon et al., 2009; Woolman et al.,
2019). Part of this mild increase in perioperative morbidity and mor-
tality in 22q11.2 DS is related to the associated immunodeficiency
and increased risk of postoperative infection (Naimo et al., 2016).
CHARGE and 22q11.2 DS show clinical overlap in immunodeficiency
(Chopra, Baretto, Duddridge, & Browning, 2009; Hsu et al., 2016;
Jyonouchi et al., 2009; Wong et al., 2015), though immune
deficits tend to be less severe in CHARGE syndrome (Hsu et al.,
2016). Together, these data suggest only minor contribution of immu-
nodeficiency to peri-operative and long-term outcomes in CHARGE
syndrome.
Outcomes for individuals with CHARGE syndrome are typically
significantly worse than for those with 22q11.2 DS (Michielon et al.,
2009), suggesting additional factors that separate these syndromes
likely influence the clinical course. There are key differences between
CHARGE and 22q11.2 DS in terms of the types of airway malformations
(e.g., choanal atresia, vascular rings, and tracheobronchomalacia), feed-
ing difficulties, and involvement of cranial nerves IX and X which can
impart particular morbidity and mortality among CHARGE patients
(K. Blake et al., 2009; Corsten-Janssen, Kerstjens-Frederikse, et al.,
2013; Corsten-Janssen, Saitta, et al., 2013; Corsten-Janssen et al.,
2016; Hudson, Macdonald, Friedman, & Blake, 2017; Stack & Wyse,
1991). In combination, these create a particularly high risk of postop-
erative airway events and aspiration, especially after cardiac surgery
(Blake et al., 2009). Such events are a primary cause of death cited in
the limited studies of postsurgical and long term outcomes in individ-
uals with CHARGE (Bergman et al., 2010; Blake et al., 1990; Tellier
et al., 1998; Wyse et al., 1993). Additionally, there is evidence that
CHD7 plays a role in response to ischemia as evidence in negative
regulation of angiogenesis in the peri-necrotic regions of glioblastoma
(Boyd et al., 2019), which may play a role in cardiac recovery and rem-
odeling after cardiac surgery. Therefore, pre- and postoperative man-
agement should include a focus on prevention of aspiration as a
primary means of decreasing mortality in CHARGE patients, particu-
larly after cardiac surgery.
4 | CONCLUSION
CHARGE syndrome has widely variable phenotypes in congenital
heart disease. The spectrum of congenital heart defects appears to be
secondary to chromatin signaling altering the migration and develop-
ment of the neural crest cell lineage and cardiac mesoderm. However
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due to the rarity of CHARGE syndrome and spectrum of pathogenic
variants, understanding the full genotype–phenotype association
within congenital heart disease and the other systems affected by
CHARGE syndrome requires a coordinated effort to pool data across
large cohort and case series studies. This effort would be enhanced
by publication of descriptive datasets in supporting Information to
allow for meta-analysis. Despite the wide variation in congenital heart
defects in CHARGE syndrome, there is a bias toward complex con-
genital heart disease (e.g., conotruncal defects and AVSDs) that
require major and often repeated cardiac surgical repair, which can
impart considerable morbidity and mortality to individuals with
CHARGE syndrome. However, poor postoperative outcomes from
neonatal cardiac repair appear to be primarily driven by noncardiac
risk factors. Understanding these risk factors can be critical for mini-
mize the postoperative risk for these individuals, particularly the risk
of aspiration and airway complications.
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